Esanex Garners $10,746,664 New Financing

  • Feed Type
  • Date
    12/12/2012
  • Company Name
    Esanex
  • Mailing Address
    115 W. Washington St. Indianapolis, IN 46204 USA
  • Company Description
    Esanex is a biotechnology company developing a best-in-class Hsp90 inhibitor to fight various forms of cancer.
  • Website
    Undisclosed
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $10,746,664
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing.
  • M&A Terms
  • Venture Investor

Trending on Xconomy